Azithromycin News and Research RSS Feed - Azithromycin News and Research

Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
Study: Extended azithromycin therapy may offer significant benefits to COPD patients

Study: Extended azithromycin therapy may offer significant benefits to COPD patients

Extended use of a common antibiotic may prolong the time between hospitalizations for patients suffering from chronic obstructive pulmonary disease, according to a post-hoc analysis of a multicenter study which compared the hospitalization rates of patients treated with a 12-month course of azithromycin to the rates of those treated with placebo. [More]

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery. [More]
Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila. [More]

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA. [More]

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic erythromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA. [More]

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013. [More]
Disease eradication efforts set sights on polio, Guinea worm

Disease eradication efforts set sights on polio, Guinea worm

"It's not a race, exactly, but there's an intriguing uncertainty about whether a former U.S. president or a software magnate will cause the next deliberate extinction of a species in the wild. Will Jimmy Carter eradicate Guinea worm before Bill Gates eradicates polio?" Wall Street Journal commentator Matt Ridley asks in his "Mind & Matter" column. [More]
UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations. [More]

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision Incorporated today announced that patient enrollment has been completed in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery. [More]
Positive results from Cempra's IV solithromycin Phase 1 study

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations. [More]

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012. [More]
Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Although people often say they have "strep" throat, most sore throats actually are caused by a virus, not streptococcus bacteria, and shouldn't be treated with antibiotics, suggest guidelines published by the Infectious Diseases Society of America (IDSA). Antibiotics are ineffective against viruses. [More]

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis. [More]
DuraSite 2 ophthalmic drug delivery system from InSite Vision

DuraSite 2 ophthalmic drug delivery system from InSite Vision

InSite Vision Incorporated today introduced DuraSite 2, its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics. [More]

Promising new treatment for bronchiectasis

Researchers have identified a promising new treatment for non-cystic fibrosis bronchiectasis, a long-term lung disorder which causes persistent coughing and breathlessness. The results, published in The Lancet, could represent an important advance in the treatment of this debilitating disease, for which very few evidence-based treatments are currently available. [More]

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012. [More]

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery. [More]

Azithromycin can be effective treatment option for patients with BOS

Researchers in the United Kingdom have determined that azithromycin, a broad-spectrum antibiotic that also has anti-inflammatory properties, can be an effective treatment option for patients suffering from bronchiolitis obliterans syndrome (BOS), a life-threatening complication that occurs in the majority of patients following lung transplantation. [More]
Treating prenatal maternal infections could improve birth outcomes, study suggests

Treating prenatal maternal infections could improve birth outcomes, study suggests

Clinical trials are underway to test an azithromycin-based combination treatment for pregnant women, "which could tackle some of the leading preventable causes of death for babies in sub-Saharan Africa," according to researchers from the London School of Hygiene & Tropical Medicine (LSHTM), who published a report on Wednesday in the Journal of the American Medical Association. [More]

Dual prevalence of STIs/RTIs and malaria in pregnancy found among women in sub-Saharan Africa

A review of studies reporting estimates of the prevalence of sexually transmitted infections/reproductive tract infections (STIs/RTIs) and malaria over the past 20 years suggests that a considerable burden of malaria and STIs/RTIs exists among pregnant women attending antenatal (before birth) facilities in sub-Saharan Africa, according to a review and meta-analysis of previous studies published in the May 16 issue of JAMA, a theme issue on Global Health. [More]